Rocket Pharmaceuticals is trading 5.5% down at $3.24 now, with the decline appearing driven mainly by broader risk-off conditions.
- FDA alignment announced September 15, 2026, for the RP-A501 Danon disease Phase 2 trial supports continued dosing.
- Nine patients remain to enroll, with dosing expected to finish by mid-2027.
- Rising yields, oil prices, and Federal Reserve uncertainty are pressuring growth-oriented healthcare stocks.